A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin) in Subjects With Peritoneal Carcinomatosis From Colorectal Carcinoma Following Hyperthermic Intraperitoneal Chemotherapy
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2019
Price : $35 *
At a glance
- Drugs Radspherin (Primary)
- Indications Carcinoma; Colorectal cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Oncoinvent
- 26 Jun 2019 Planned End Date changed from 1 Feb 2022 to 1 Jan 2023.
- 26 Jun 2019 Planned primary completion date changed from 1 Oct 2020 to 1 Dec 2020.
- 26 Jun 2019 Planned initiation date changed from 1 Feb 2019 to 15 Dec 2019.